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Abstract
Background: Progranulin (PGRN) is a secreted growth factor important for neuronal survival and may do so, in part,
by regulating lysosome homeostasis. Mutations in the PGRN gene (GRN) are a common cause of frontotemporal lobar
degeneration (FTLD) and lead to disease through PGRN haploinsufficiency. Additionally, complete loss of PGRN in
humans leads to neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disease. Importantly, Grn−/− mouse models
recapitulate pathogenic lysosomal features of NCL. Further, GRN variants that decrease PGRN expression increase the
risk of developing Alzheimer’s disease (AD) and Parkinson’s disease (PD). Together these findings demonstrate that
insufficient PGRN predisposes neurons to degeneration. Therefore, compounds that increase PGRN levels are potential
therapeutics for multiple neurodegenerative diseases.
Results: Here, we performed a cell-based screen of a library of known autophagy-lysosome modulators and identified
multiple novel activators of a human GRN promoter reporter including several common mTOR inhibitors and an
mTOR-independent activator of autophagy, trehalose. Secondary cellular screens identified trehalose, a natural
disaccharide, as the most promising lead compound because it increased endogenous PGRN in all cell lines
tested and has multiple reported neuroprotective properties. Trehalose dose-dependently increased GRN mRNA
as well as intracellular and secreted PGRN in both mouse and human cell lines and this effect was independent
of the transcription factor EB (TFEB). Moreover, trehalose rescued PGRN deficiency in human fibroblasts and
neurons derived from induced pluripotent stem cells (iPSCs) generated from GRN mutation carriers. Finally, oral
administration of trehalose to Grn haploinsufficient mice significantly increased PGRN expression in the brain.
Conclusions: This work reports several novel autophagy-lysosome modulators that enhance PGRN expression and
identifies trehalose as a promising therapeutic for raising PGRN levels to treat multiple neurodegenerative diseases.
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Background
Progranulin is a multi-functional, secreted glycoprotein
involved in cell survival, modulation of inflammation,
and neuroprotection [1, 2]. Mutations in the human
GRN gene are one of the most common causes of fron-
totemporal lobar degeneration (FTLD) and the vast ma-
jority cause loss of function by decreasing GRN mRNA
and PGRN protein by at least 50 % via haploinsufficiency
[3–5]. Decreased PGRN expression is also implicated as
a risk factor for Alzheimer’s disease (AD) and Parkinson’s
disease (PD) [6–8]. In the brain, PGRN is expressed
predominantly in neurons and microglia. FTLD-GRN
pathology is characterized by neurodegeneration, neuroin-
flammation, and intra-neuronal and glial inclusions con-
taining the TAR DNA-binding protein 43 (TDP-43), the
autophagy adaptor protein p62/SQSTM1, and ubiquiti-
nated proteins (reviewed in [9]). Accumulation of these
proteins suggests that defects in protein removal systems,
such as the autophagy-lysosome pathway, may contribute
to disease. In support of this, abnormal accumulation
of lysosomal proteins and lipofuscin, an age-related
lipid-containing residue of lysosomal digestion, occur
in Grn−/− mice and human FTLD-GRN brains [10].
Moreover, complete loss of PGRN causes neuronal ceroid
lipofuscinosis (NCL) [11], an early-onset lysosomal storage
disease. Together, these data indicate that PGRN plays a
critical, yet undefined role in lysosome function and
homeostasis.
The identification of small molecules to raise PGRN
protein levels is an attractive therapeutic strategy for
neurodegeneration caused by PGRN deficiency. Currently,
there are no clinically approved methods to increase
PGRN in patients with FTLD-GRN. In this study, we
screened a library of small molecule modulators of the
autophagy-lysosome pathway to identify novel enhancers
of PGRN expression. The top compounds identified in the
screen were further tested in secondary cellular screens
and relevant models of GRN deficiency, including patient




Bafilomycin A1 (BafA1), PP242, and Torin1 were ob-
tained from Tocris (R&D Systems, Minneapolis, MN).
Chloroquine diphosphate and Actinomycin D (ActD)
were obtained from Sigma (St. Louis, MO). Suberanilo-
hydroxamic acid (SAHA or vorinostat) and rapamycin
were obtained from LC Laboratories (Woburn, MA). Tre-
halose (dihydrate) was obtained from Sigma or Brooklyn
Premium (Brooklyn, NY). BafA1, PP242, Torin1, rapamy-
cin, and SAHA were dissolved in DMSO and stocks were
frozen at −20 °C. Chloroquine and trehalose were dis-
solved in ultrapure Milli-Q water (EMD Millipore) and
frozen at −20 °C or filtered (0.22-μm) and stored at 4 °C,
respectively. Trehalose stocks were made up fresh as
needed.
Cell culture
Human embryonic kidney cells (HEK293T; American
Type Culture Collection), human HeLa cells (American
Type Culture Collection), human neuroglioma cells (H4;
American Type Culture Collection), and mouse neuro-
blastoma cells (N2a; American Type Culture Collection)
were cultured in high glucose Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10 % FBS,
1 % penicillin/streptomycin, and 1 % Gluta-max. Human
neuroblastoma cells (SH-SY5Y; American Type Culture
Collection) were cultured in DMEM/Ham’s F12 1:1
medium supplemented with 10 % FBS and 1 % penicillin/
streptomycin. The TFEB-GFP stable HeLa cell line [12]
was a kind gift provided by Dr. Shawn Ferguson (Yale
University) and was cultured in high glucose Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with
10 % FBS, 1 % penicillin/streptomycin, and 1 % Gluta-
max. The HAP1 human haploid cell lines were purchased
from Horizon Discovery Group. The TFEB knock-out cell
line was produced by CRISPR/Cas9 gene editing which in-
troduced a frameshift mutation into the coding sequence
(7 bp deletion in exon 2) of TFEB. HAP1 cells were cul-
tured in Iscove’s Modified Dulbecco’s Medium (IMDM)
supplemented with 10 % FBS and 1 % penicillin/
streptomycin. Primary mouse cortical neurons (embryonic
day 18) were a generous gift from Dr. Randy Hall (Emory
University). All cell lines were maintained at 37 °C with
5 % CO2.
Human fibroblast biopsy and culture
Human dermal fibroblasts were collected under protocol
00064365 as approved by the Emory University Institu-
tional Review Board. Informed written consent was ob-
tained for all research subjects. A 2-mm dermal punch
biopsy was taken from each subject under sterile condi-
tions. The biopsy sample was placed in culture medium
(DMEM with 4.5 mg/mL glucose, L-glutamine, and sodium
pyruvate) with or without 0.6 % v/v fungizone (Gibco).
Culture media was supplemented with 10 % FBS (Atlanta
Biologicals) and 1 % penicillin/streptomycin (Gibco) and
filtered through a 0.2-μm syringe filter prior to use. In a
culture hood, skin biopsies were rinsed 3× with sterile PBS
and the skin biopsy was then transferred to a single
well of a 6-well culture dish in ~50-100 μL PBS or cul-
ture medium. The tissue was cut into several smaller pieces
using a sterile rounded-tip scalpel blade. A sterile glass
coverslip (25 mm) was placed on top of the skin pieces and
pressed down onto the dish to secure the sample. Carefully,
3 mL of culture medium was added to the well and the
plate was placed in an incubator at 37 °C with 5 % CO2.
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The cultures were allowed to sit undisturbed for 6–7 days
and then half of the media was removed and replaced with
fresh media. Fibroblasts typically emerged by day 10 and
were ready to passage by day 12–16. Fibroblast cultures
were passaged as needed using 0.25 % trypsin with EDTA
(Invitrogen) and gradually scaled up to larger culture dishes
in culture medium without fungizone. Individual cell plugs
from each line were then cryopreserved at low passage
numbers, typically at P < 5. Fibroblast lines were gener-
ated from 3 patients with the following GRN mutations:
c.1477C > T (R493X) (designated GRN #1, GRN #2)
and c.592_593delAG (R198GfsX19) (designated GRN #3).
Induced pluripotent stem cell (iPSC) generation and
characterization
One control and one GRN (GRN #3) fibroblast line were
reprogrammed into iPSCs using the Cytotune 2.0 Kit
(Life Technologies) per the manufacturer’s protocol. In
brief, early passage fibroblast (P < 10) were grown to ap-
proximately 50–80 % confluency in fibroblast medium
consisting of 10 % ES-qualified FBS (Life Technologies,
0.1 mM NEAA, 55 μM β-mercaptoethanol, high glucose
DMEM (Life Technologies). On Day 0, fibroblasts were
transduced with three Sendai viruses encoding Klf4–
Oct3/4–Sox2 (KOS), hc-Myc, and hKlf4, each at an
MOI of 5). Cells were fed with fibroblast medium every
other day for 7 days. On day 7, cells were passaged onto
vitronectin (Life Technologies) coated dishes at a density
of 2.5 × 105 - 5.0 × 105 cells/well. Beginning on day 8,
cells were fed every day in Essential 8 medium (Life
Technologies). Resulting iPS colonies were manually
picked and transferred to a dish coated with either vitro-
nectin or Matrigel (BD). iPSCs were maintained on
Matrigel coated dishes and mTesR1 medium (Stem Cell
Technologies) and passaged every 5–7 days.
iPSC neuronal differentiation
Prior to differentiation, iPSC colonies were treated with
10 μM ROCK inhibitor, Y-27632 (Stem Cell Technologies),
for ~1 h. iPSCs were then treated with Accutase (Stem Cell
Technologies) for ~8 min to obtain a single cell suspen-
sion. Cells were spun out of Accutase and resuspended in
N2B27 differentiation medium (1:1 Advanced DMEM-
F12/Neurobasal, 1× N2, 1× B27, 0.2 % Penstrep, 1× Gluta-
max, 110 μM β-mercaptoethanol) and seeded in 10 cm
Ultra-Low Attachment dishes (Corning) in order to form
embryoid bodies. Cells were maintained as embryoid
bodies throughout the differentiation and were fed every
2 days. For the first 2 days, the differentiation medium
contained a final concentration of 3 μM CHIR99021
(Stem Cell Technologies), 10 μM SB431542 (Stem Cell
Technologies), 10 μM LDN193189 (Stemgent), 0.4 μg/mL
Ascorbic Acid (Sigma), 10 μM Y-27632. On Day 2, 1 μM
Retinoic Acid (Sigma) and 500 nM Smoothened Agonist
(Millipore) were added to the medium. On Day 4,
CHIR99021 was removed from the medium. On Day 8,
SB and LDN were removed from the medium and the
following supplements were added: 10 ng/mL BDNF
(Peprotech), 10 ng/mL GDNF (Peprotech), and 10 μM
DAPT (Tocris). On day 18, embryoid bodies were disasso-
ciated to single cells using papain/DNase (Worhtington
Bio) and plated on polyornithine/laminin coated glass
coverslips or cell culture plates. Neurons were typically
used for experiments around 1-week post-plating.
Chemical library screen
HEK293T cells were plated in a 96-well plate at approxi-
mately 1.5 × 104 cells per well in complete medium. The
following day, cells were transfected with 100 ng of the
GLuc-ON human PGRN promoter (Gene Accession:
NM_001012479; promoter length: 1253 bp; sequence
verified) dual reporter (GLuc/SEAP) plasmid (Genecopoeia)
using Mirrus LT1 transfection reagent. 24 h after transfec-
tion, a commercially available library of ~100 reported
chemical enhancers or inhibitors of the autophagy pathway
(Enzo Screen-Well library; BML-2837) were applied to the
cells overnight for 16 h. Final concentration for all drugs
were 1 μM except for bafilomycin A1 (50 nM), chloroquine
(50 μM), and trehalose (100 mM) based on previously pub-
lished reports for increasing progranulin expression or
activating autophagy (see main text). After treatment, the
media was collected and transferred to a new 96-well plate,
spun briefly to remove cell debris, and 10 μL of each
sample was transferred to a new 96-well black plate.
Secreted GLuc activity normalized to SEAP was measured
for each compound using the SecretePair Dual Lumines-
cence Assay Kit (GeneCopoeia) on a BioTek Synergy plate
reader and compared to mock-treated (DMSO) cells. The
screen was performed in two independent experiments and
the average fold-increase compared to mock treatment is
reported. Staurosporine (1 μM) was used as a control for
overt cell toxicity and compounds whose individual GLuc
or seAP values were below those of staurosporine were
omitted.
Cell lysis and Western blotting
Cells were rinsed 2× in PBS and lysed in ice-cold RIPA
buffer (50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1 %
Triton-×100, 0.1 % SDS, 0.5 % sodium deoxycholate) in
the presence of protease and phosphatase inhibitor cock-
tail (PPIC, Pierce). RIPA lysates were sonicated at 20 %
amplitude for 5 cycles of 2 s on/2 s off on ice using a
sonic dismembrator (QSonica, LLC; Newton, Ct). In
some experiments cells were first lysed in CYTO buffer
(50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 0.5 % Triton
X-100 + PPIC) on ice for 10 min followed by centrifuga-
tion at max speed for 10 min at 4 °C. The resultant super-
natant contained cytoplasmic and membrane proteins.
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The pellet was rinsed with CYTO buffer, re-centrifuged
for 2 min and the supernatant was discarded. The pellet
was then resuspended in NUC buffer (RIPA; 50 mM
Tris–HCl, pH 8.0, 150 mM NaCl, 1 % Triton-×100,
0.1 % SDS, 0.5 % sodium deoxycholate + PPIC) and
sonicated as above to obtain a nuclear extract. GAPDH
and Histone H3 were used as protein markers for cyto-
plasmic/membrane and nuclear extraction efficiencies,
respectively. Total protein was measured by BCA assay
(Pierce) and Western blot samples were prepared with
4× loading buffer (125 mM Tris, pH 6.8, 8 % LDS, 40 %
glycerol, Orange G) and heat-denatured at 70 °C for
15 min. Samples of equal protein were run on a range
of Bio-Rad TGX mini-gels and transferred to PVDF or
Nitrocellulose membranes. Membranes were blocked
with LiCor Odyssey blocking buffer (1:1 TBS/Blocking
Buffer) for 1 h at room temperature followed by incu-
bation with primary antibody (diluted in 1:1 TBST/
Blocking Buffer) over night at 4 °C with gentle rocking.
HRP-conjugated secondaries (Jackson Labs or Cell Sig-
naling technologies) diluted in 5 % milk/TBST or LiCor
fluorescent secondaries diluted in 1:1 TBST/Blocking
Buffer were used. West Dura (Pierce) substrate was
used for chemiluminescent detection. Blots were im-
aged using an Odyssey Fc (LiCor) and analyzed using
Image Studio software (Ver 3.1) for densitometry analysis.
The following primary antibodies were used for Western
blot: LC3A/B (1:1000; CST), total 4EBP1 and P-4EBP1
(1:1000; CST), human PGRN (1:1000; R&D), PGRN/
PCDGF (1:700; Invitrogen), mouse PGRN (1 μg/mL;
R&D), total S6 and P-S6 (1:1000; CST), p62 (1:1000; BD),
TFEB (1:1000; CST), TUJ1 (1:2,000; Covance). Tubulin
(1:20,000; Epitomics), Actin (1:10,000; Epitomics), GAPDH
(1:5,000; Sigma), and Histone H3 (1:5,000; Millipore) were
used as loading controls.
Secreted progranulin measurement
Cells were plated in 6-cm dishes in complete medium.
Two days after plating, cells were washed 2× with
serum-free media and treated over night with vehicle or
drug at the indicated concentrations in serum-free
media. Cell supernatants were collected the following
day at the indicated times and immediately spun at
6000 rpm for 5 min at 4 °C to clear debris. The super-
natant (500 μL) was transferred to a 0.5 mL Amicon
Ultra concentrator (50 kDa cutoff) and spun for 5–10 min
at 14,000 × g. The spin filter was placed upside down in a
fresh tube and spun at 1000 × g for 2 min to collect the
concentrated sample. The concentrated samples were nor-
malized to total protein in the cell lysates to account for
differences in cell numbers, mixed with 4× loading buffer
to a final concentration of 1×, and heated at 70 °C for
15 min to denature.
Immunocytochemistry
H4 or primary fibroblast cells were fixed with 4 % para-
formaldehyde for 15 min. Cells were then permeabilized
with ice-cold methanol for 10 min. After blocking with
0.1 % BSA in PBS, cells were incubated with goat anti-
PGRN (1:300; R&D) in blocking buffer overnight at 4 °C.
After washing with PBS, cells were incubated in secondary
antibodies conjugated to Cy3 (1:300; Jackson Immunore-
search) and DAPI (1:1000; Life Technologies) for 1 h at
room temperature. Slides were mounted using Vectashield
Hard Set (Vector Laboratories, Inc.; Burlingame, CA).
iPSC-neurons were fixed with 4 % paraformaldehyde for
15 min. Cells were then permeabilized with ice-cold
methanol or 0.1 % triton X-100 in PBS for 10 min. After
blocking with 0.1 % BSA or 5 % Normal Donkey Serum
(NDS), cells were incubated with the following primary
antibodies in blocking buffer overnight at 4 °C: PGRN
(Goat polyclonal, 1:300; R&D), LC3A/B (1:100; CST), Tuj1
(1:2000; Covance). After washing with PBS, cells were in-
cubated in secondary antibodies conjugated to Cy5 (1:300;
Jackson Immunoresearch) or Alexa fluor 488 (1:300; Life
Technologies) for 1 h at room temperature. Slides were
mounted using ProLong Gold Antifade Reagent with
DAPI (Life Technologies). Images were collected with a
Zeiss LSM 510 NLO META system (Emory University
Integrated Cellular imaging Microscopy Core) or EVOS
FL Cell Imaging System (Life Technologies).
Quantitative real-time PCR
RNA was extracted using QiaShredder lysis buffer and
purified using RNeasy spin columns from Qiagen.
Purified RNA (900 ng) was used as a template to pro-
duce cDNA using AB high Capacity RNA-to-cDNA kit
(Life Technologies) according to the manufacturer’s
protocol on a Bio-Rad C1000 Thermo Cycler. Ap-
proximately 20 ng of cDNA was used for quantitative
real-time PCR (qPCR) experiments using Eppendorf
plates and AB Power-SYBR mix (20 μL final reaction
volume) on an Eppendorf Mastercycler ep realplex S.
Primers were obtained from IDT and used at a final
concentration of 200 nM. The following cycle condi-
tions were used for all genes: 95 °C for 10 min
followed by 40 cycles of 95 °C for 15 s and 54 °C for
60 s with a final extension step of 95 °C for 15 s and
54 °C for 60 s. The ΔΔCt method was used to calcu-
late fold changes in RNA levels compared to vehicle
treated cells after normalization to a reference gene,
U36-B. The primer sets used were reported previously
[13] as follows: human U36B-F, 5′-CGAGGGCACCT
GGAAAAC-3′; human U36B-R, 5′-CACATTCCCCC
GGATATGA-3′; human GRN-F, 5′-CAGGGACTTCC
AGTTGCTGC-3′; human GRN-R, 5′-GCAGCAGTG
ATGGCCATCC-3′.
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Enzyme-linked immunosorbent assay (ELISA)
Mouse progranulin ELISAs were purchased from Adipo-
gen (San Diego, CA) and carried out according to the
manufacturer’s protocol. Plasma samples were diluted
1:500 in 1× Diluent buffer. Brain lysates were diluted
1:50 in 1× Diluent buffer. All ELISA measurements were
done in duplicate and fell within the standard curve gener-
ated by the provided recombinant progranulin standard.
Mouse plasma and brain lysate samples were randomized
and loaded blind to the researcher. For brain and plasma
ELISAs, a positive (Grn+/+) and negative (Grn−/−)
control sample were also run to verify specificity of the
ELISA.
Animal subjects and experiments
All animal work was conducted with prior Institutional
Animal Care and Use Committee (IACUC) approval,
and was performed in accordance with PHS guidelines.
All procedures were performed under conditions de-
signed to minimize pain and distress. Emory University
is an Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC) approved institu-
tion, and follows the current version of the Guide for
the Care and Use of Laboratory Animals (8th Edition),
as adopted by the Office of Laboratory Animal Welfare
(OLAW). Twenty Grn heterozygous mice (Grn+/−) ob-
tained from our colony by crossing Grn knockout mice
(Grn−/−) [14] with wild-type C57bl6J (originally ac-
quired from The Jackson Laboratory, Bar Harbour,
Maine) were used in the study. We elected to use both
male and female mice in approximately equal numbers
based on the number of animals available in the colony
and to comply with recent NIH guidance on maintaining
gender balance in biomedical animal studies. For treat-
ments, solutions of 2 % sucrose or 2 % trehalose were
made up in water (same regularly provided to animals in
the vivarium) and filtered through a 0.2-μm stericup fil-
ter. Fresh water was changed out once per week.
Weights of the water bottles were measured before and
after each exchange to estimate amount of water con-
sumed per group. Mice were weighed periodically to
monitor changes in weight gain per group. After 65 days
of treatment, mice were euthanized by decapitation after
anesthetization with isoflurane. Blood was collected at
time of death in a reservoir containing 100 μL of 0.5 M
EDTA. Plasma was separated by centrifugation at 3000 rpm
for 15 min at 4 °C and stored at −80 °C. Whole brain was
harvested and separated into hemispheres after removal of
the cerebellum. One half of the brain was drop fixed in 4 %
paraformaldehyde (PFA) and the other half was placed in a
tube, snap frozen in liquid nitrogen, and stored at −80 °C.
Frozen brain tissue was ground under liquid nitrogen with
a mortar and pestle to create a uniform powder. For protein
extraction, approximately 50 mg of tissue powder was
homogenized in lysis buffer containing 50 mM Tris–HCl
(pH 7.4), 150 mM NaCl, 1 % Triton X-100 and complete
protease and phosphatase inhibitor cocktail (Pierce) and
sonicated briefly. Protein concentrations were determined
by BCA assay (Pierce) and Western blot samples were
made up as described above. Approximately 25 μg of
total protein per sample was loaded onto a 12 % TGX
mini gel (Bio-Rad) for Western blotting as described
above.
Statistical analysis
All values are expressed as the mean ± SEM. For experi-
ments where two groups were compared, a standard
two-tailed Student’s t-test was used to measure signifi-
cance. For comparisons of more than two groups, one-
way analysis of variance (ANOVA) was used followed by
Dunnet’s or Tukey’s comparison post-hoc test. For correl-
ation analysis, Pearson’s r was used. All statistical analyses
were performed in GraphPad Prism 6.02 (GraphPad
Software, La Jolla, California, USA). A P-value <0.05 was
considered significant.
Results
Identification of novel autophagy-lysosome modulators
that increase PGRN
PGRN partially localizes to late endosomal and lyso-
somal compartments within neurons [15, 16] and loss of
PGRN causes lysosome dysfunction; therefore, we hy-
pothesized that modulators of this pathway may also
regulate GRN expression [11, 17, 18]. To test this hy-
pothesis, we expressed a dual reporter construct (Fig. 1a)
in HEK293T cells to monitor activity of the human GRN
promoter and screened a custom chemical library of
autophagy-lysosome modulators (see Methods section).
We identified several compounds that increased reporter
activity ~2-fold (Fig. 1b), comparable to suberoylanilide
hydroxamic acid (SAHA), a histone deacetylase inhibitor
(HDAC) which was previously identified as a robust regu-
lator of GRN transcription in a high-throughput screen
(HTS) of the Prestwick chemical library [13]. The top hits
from our screen were Torin1, a mechanistic target of rapa-
mycin (mTOR) inhibitor [19], and trehalose, an mTOR-
independent activator of autophagy [20]. The mTOR
kinase is a principle negative regulator of autophagy and
numerous autophagy activators have been discovered that
work via inhibiting mTOR and downstream signaling
pathways (reviewed in [21]). We found that several other
compounds that reportedly inhibit mTOR also increased
GRN promoter activity (Additional file 1: Table S1),
suggesting this signaling pathway may be involved in regu-
lating GRN expression.
Next, we used a secondary cellular screen to determine
whether identified compounds increased endogenous
levels of PGRN. We treated human H4 neuroglioma
Holler et al. Molecular Neurodegeneration  (2016) 11:46 Page 5 of 17
cells with SAHA, trehalose, or the mTOR inhibitors
rapamycin, PP242, or Torin1 for 24 h and monitored au-
tophagy activation and PGRN expression by immunoblot
(Fig. 1c). The conversion of the microtubule-associated
protein light chain 3 from a non-lipidated form (LC3-I)
to a lipidated membrane-bound form (LC3-II) correlates
with the formation of autophagosomes and is used as a
marker for autophagy [22]. All compounds resulted in
increased levels of LC3-II and decreased levels of p62,
an autophagic substrate, indicating autophagy activation.
Trehalose had no effect on phosphorylation of S6 ribo-
somal protein (P-S6), a downstream target of mTOR,
confirming that activation of autophagy was independent
of mTOR inhibition. Further, trehalose and mTOR
Fig. 1 Identification and validation of small molecule autophagy-lysosome modulators that increase PGRN. a Schematic of the human GRN promoter
dual reporter plasmid used for identifying compounds that affect PGRN expression at the transcriptional level. Secreted Gaussia Luciferase (GLuc)
activity monitors GRN promoter activity while secreted Alkaline Phosphatase (SEAP) activity monitors transfection efficiency and is used for
normalization. b Fold-change in reporter expression activity (GLuc/SEAP) after transfection into HEK293T cells followed by treatment with a
custom library of autophagy-lysosome modulators. SAHA (1 μM), which increases GRN transcription, was used as a positive control for the reporter
assay. Bafilomycin A1 (50 nM) and chloroquine (50 μM), which increase PGRN expression primarily via a post-transcriptional mechanism, were included
as negative controls. Trehalose was used at 100 mM, as reported in the literature for inducing autophagy. All other compounds were used at 1 μM.
The data presented are the average of two independent replicates of the drug screen. c Immunoblot of cell lysates and conditioned media (bottom)
from human neuroglioma (H4) cells treated with vehicle, SAHA (1 μM), rapamycin (1 μM), PP242 (1 μM), Torin1 (1 μM), or trehalose (100 mM) for 24 h.
Immunoblot of cell lysates from d human neuroblastoma cells (SH-SY5Y) cells and e mouse neuroblastoma cells (N2a) treated as in c. f Immunoblot of
cell lysates from primary mouse cortical neurons (E18) treated for 24 h with vehicle, trehalose (100 mM), or PP242 (1 μM). In c-f, p62 and/or LC3-II were
used to monitor autophagy induction and P-S6 and/or P-4EBP1 were used to assess mTOR inhibition. Immunoblot images are representative of at least
two independent experiments
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inhibitors increased both intracellular and secreted
PGRN (Fig. 1c and Additional file 1: Figure S1a). Im-
portantly, trehalose also increased PGRN in human
(Fig. 1d) and mouse (Fig. 1e) neuroblastoma cell lines,
and in mouse primary cortical neurons (Fig. 1f ). In con-
trast, mTOR inhibitors failed to increase PGRN in these
cell lines even though increased LC3-II was observed
(Fig. 1d–f ). These data indicate a mechanistic difference
between trehalose and mTOR inhibitors in cells of the
neuronal lineage and that mTOR-inhibition and PGRN
upregulation are independent pathways. Thus, we fo-
cused on trehalose as our lead molecule because it had
consistent and robust effects on PGRN levels across
multiple disease-relevant cell types.
Trehalose increases PGRN expression via a transcriptional
mechanism
Next, we characterized the activity of trehalose in cul-
tured cells in more detail. Using bafilomycin A1 (BafA1)
to block autophagosome fusion with lysosomes, we
found that trehalose increased autophagic flux in H4
cells (Additional file 1: Figure S2a-b), consistent with
previous reports that trehalose likely acts at the step of
autophagy initiation [23, 24]. In addition, treatment of
H4 cells with trehalose had no overt effect on lysosomal
acidification based on LysoTracker Red staining, unlike
the vacuolar-ATPase inhibitor BafA1 (Additional file 1:
Figure S2c). Therefore, it is likely that trehalose and the
previously reported BafA1 have different mechanisms of
action for increasing PGRN [25]. Finally, dose- or time-
dependent treatment of H4 cells with trehalose did not
affect cell viability (Additional file 1: Figure S2d). Over-
all, these results confirm that trehalose is well tolerated
by mammalian cells.
Next, we found that trehalose significantly increased
PGRN in a dose- (Fig. 2a–b) and time- (Fig. 2e–f )
dependent manner that coincided with increased LC3-II
(Fig. 2a, c and Fig. 2e, g). Once again, this effect was in-
dependent of mTOR inhibition as measured by phos-
phorylated 4EBP-1, a direct target of mTOR (Fig. 2a, d
and Fig. 2e, h). A significant increase in LC3-II was ob-
served prior to an increase in PGRN, indicating that ac-
tivation of autophagy may precede PGRN upregulation.
The dose- and time-dependent effects of trehalose on
PGRN were confirmed in both human and mouse neuro-
blastoma cell lines as well (Additional file 1: Figure S3a-c).
H4 cells treated with trehalose showed a robust increase
in intracellular PGRN by immunocytochemistry, con-
firming the immunoblot data (Fig. 2i). Importantly, we
observed a dose-dependent increase of secreted PGRN
in the media of H4 cells treated with trehalose (Fig. 2j–k).
Finally, we found that trehalose increased GRN mRNA in
a dose-dependent manner in H4 cells (Fig. 3a) and human
neuroblastoma cells (Additional file 1: Figure S3d) using
quantitative real-time PCR (qPCR). Treatment of H4 cells
with actinomycin D, an inhibitor of mRNA transcription,
blocked the trehalose-mediated increase of PGRN (Fig. 3b).
These data provide further evidence that trehalose pri-
marily acts by increasing GRN gene transcription and
supports the validity of our initial GRN promoter re-
porter assay.
The transcription factor EB (TFEB) does not mediate
trehalose-induced upregulation of PGRN
The transcription factor EB (TFEB) has been described
as a master regulator of autophagy-lysosomal gene ex-
pression [26, 27] and implicated in regulation of GRN
transcription [26, 28]. In addition, loss of PGRN has
been linked to TFEB activation [29] and trehalose has
been reported to activate TFEB in cultured cells [30, 31].
Therefore, we sought to explore whether TFEB plays a
role in mediating the trehalose-induced upregulation of
PGRN. First, we measured the levels of GRN mRNA and
PGRN protein in cultured HeLa cells stably overex-
pressing TFEB-GFP [12] compared to wild-type (WT)
HeLa cells. We found that the TFEB-GFP HeLa cells
had a small, but significant increase in both GRN
mRNA and PGRN protein compared to wild-type
HeLa cells (Fig. 4a–c), indicating that TFEB overex-
pression modulates PGRN expression via direct or in-
direct mechanisms.
Under basal conditions, TFEB is normally phosphory-
lated by several kinases, including mTOR, which retains
TFEB in the cytoplasm. Upon nutrient starvation or
pharmacological inhibition of mTOR, TFEB is dephos-
phorylated and translocates to the nucleus where it acti-
vates transcription of its gene targets [12, 32, 33]. To
test whether trehalose activates TFEB, we treated TFEB-
GFP HeLa cells with Torin1 or trehalose and monitored
TFEB-GFP localization using fluorescence microscopy.
While Torin1 robustly increased TFEB nuclear loca-
lization by 2 h, trehalose treatment only resulted in a
diffuse nuclear TFEB-GFP signal by 24 h of treatment
(Fig. 4d). Fractionation of treated TFEB-GFP HeLa cells
into cytoplasmic/membrane and nuclear fractions re-
vealed that trehalose treatment increased nuclear TFEB
levels slightly whereas Torin1 significantly increased nu-
clear TFEB levels (Fig. 4e–f ). In contrast, trehalose treat-
ment robustly increased PGRN levels, significantly more
than Torin1 treatment (Fig. 4e–f ), indicating that the
amount of TFEB in the nucleus does not correlate with
PGRN expression.
Finally, to directly address the role of endogenous
TFEB on trehalose-mediated PGRN upregulation we uti-
lized a human haploid cell line (HAP1) deficient in
TFEB (TFEB KO) that was generated using CRISPR/
Cas9. First, we confirmed by immunoblot that TFEB was
not expressed in HAP1 TFEB KO cells (Fig. 4g). We
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then treated HAP1 wild-type (WT) or TFEB KO cells
with vehicle or trehalose and measured GRN mRNA and
PGRN protein levels. TFEB KO cells showed no signifi-
cant decrease in GRN mRNA or PGRN protein levels
compared to WT cells (Fig. 4h, j). However, trehalose
treatment significantly increased GRN mRNA levels in
both cell lines to similar levels (Fig. 4h). Accordingly, we
found that trehalose was able to robustly increase PGRN
protein expression in TFEB KO cells to the same level as
in WT cells (Fig. 4i–j). Taken together, these results
demonstrate that trehalose is a relatively weak activator
of TFEB and that activation of TFEB is not responsible
for the trehalose-induced upregulation of GRN/PGRN
expression in cultured cells.
Trehalose increases PGRN expression in GRN
haploinsufficient patient-derived cells
We then asked if trehalose could rescue PGRN deficiency
in an in vitro GRN haploinsufficient model. Human pri-
mary fibroblast cell lines were generated from 3 control
(CTL) or 3 progranulin mutation (GRN) carriers with the
following GRNmutations: c.1477C >T (R493X) (designated
GRN #1, GRN #2) and c.592_593delAG (R198GfsX19)
(designated GRN #3). Intracellular PGRN protein was re-
duced ~50 % in the GRN lines compared to CTL lines
(Fig. 5a–b). However, secreted PGRN levels were re-
duced by nearly 80 % in GRN lines compared to CTL
lines (Fig. 5a, c), which is comparable to circulating PGRN
levels in human patients with GRN mutations [34–36]
Fig. 2 Trehalose induces a dose- and time-dependent increase in PGRN expression in cultured cells. a Immunoblot of cell lysates from H4 cells
treated with 0, 25, 50, or 100 mM trehalose for 20 h. Quantification of b PGRN, c LC3-II, and d p-4EBP1 immunoreactivty from a (n = 3 independent
experiments). e Immunoblot of cell lysates from H4 cells treated with 100 mM trehalose for 0, 8, 16, or 24 h. Quantification of f PGRN, g LC3-II, and h
p-4EBP1 immunoreactivity from e (n = 3 independent experiments). i Representative image of H4 cells treated with vehicle or trehalose (100 mM) for
24 h followed by staining with an antibody against human PGRN (red). Nuclei (blue) are stained with DAPI, 4’,6-diamidino-2-phenylindole. Scale bar, 10 μm.
j Immunoblot of conditioned media from H4 cells treated with 0, 50, or 100 mM trehalose for 20 h. k Quantification of secreted PGRN immunoreactivity
from Western blots of conditioned media in j (n = 3 independent experiments). In all graphs, the bars represent the mean ± SEM. *Differs from
control, P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 using one-way ANOVA followed by Dunnett’s comparison post-hoc test
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and may reflect a defect in exosome secretion [37].
Treatment of GRN fibroblasts with trehalose signifi-
cantly increased intracellular and secreted PGRN com-
pared to vehicle treated GRN fibroblasts (Fig. 5a–c).
Additionally, GRN mRNA from GRN fibroblasts, which
was reduced by ~55 % compared to CTL fibroblasts,
was significantly increased to near CTL levels after tre-
halose treatment (Fig. 5d). Immunocytochemistry of
primary human fibroblasts revealed a robust increase in
PGRN staining in GRN cells treated with trehalose,
similar to vehicle treated CTL cells (Fig. 4e).
Next, we reprogrammed one CTL and one GRN
(GRN #3) fibroblast line to generate induced pluripo-
tent stem cells (iPSC) and derived neurons from each
line using an embryoid body-based differentiation protocol
(Fig. 6a–b). Treatment of the GRN embryoid bodies (EBs)
with trehalose restored PGRN to CTL levels, whereas
PP242 failed to increase PGRN (Fig. 6c), similar to what
we observed in neuronal-like cells. In GRN iPSC-neurons,
PGRN expression was detected in the cell body and pro-
cesses (Additional file 1: Figure S4a) and expression was
reduced compared to the CTL line (Fig. 6d). Treatment of
GRN iPSC-neurons with trehalose for 24 h lead to a sig-
nificant increase in PGRN (Fig. 6d–e) and LC3-II (Fig. 6d
and Additional file 1: Figure S4b), indicating autophago-
some induction. Overall, these data show that trehalose
can rescue PGRN deficiency in cell-based models of
GRN haploinsufficiency, including iPSCs and iPSC-
derived neurons.
Trehalose increases PGRN expression in vivo in a mouse
model of Grn haploinsufficiency
To extend our observations to an in vivo model, we
treated three-month old Grn+/− mice with 2 % trehalose
water (Trehalose, n = 7; 3 M/4 F) ad libitum for 65 days
and then analyzed changes in PGRN levels in the brain
and plasma. As controls, additional mice were treated
with normal drinking water (Vehicle, n = 6; 3 M/3 F) or
2 % sucrose water (Sucrose, n = 7; 3 M/4 F). Similar
treatment paradigms in mouse models have shown that
trehalose can enhance autophagy [24, 38] and reduce
pathologies [24, 39, 40], without adverse effects [41, 42].
In our study, mice treated with trehalose or sucrose con-
sumed slightly more water than vehicle mice (Additional
file 1: Figure S5a), although changes in body weight were
not significant (Additional file 1: Figure S5b–c). Strikingly,
PGRN levels in brain tissue were significantly increased in
only the trehalose treated mice by both immunoblot
(Fig. 7a–b) and ELISA (Fig. 7c), with both measures posi-
tively correlating (Fig. 7d). We also measured PGRN in
plasma by ELISA but found no significant differences
across groups (Additional file 1: Figure S5d). This discord-
ance could be due to the fact that circulating plasma PGRN
levels do not reflect brain/CSF PGRN levels [43, 44].
Finally, LC3-II was significantly increased in brain tissue of
the trehalose treated mice (Fig. 7a, e), which was positively
correlated with PGRN by immunoblot (Fig. 7f ). Taken
together, our results demonstrate that oral administra-
tion of trehalose increases brain PGRN levels and au-
tophagic markers in vivo.
Discussion
Reduced PGRN in the brain is linked to neurodegenera-
tion in FTLD, AD, PD, and NCL. Therefore, increasing
PGRN expression may be a viable therapeutic strategy to
prevent or treat multiple neurodegenerative diseases. In
support of this, expression of PGRN cDNA in an iPSC
model of FTD-GRN rescued cortical neuron generation
[45]. Further, viral mediated PGRN overexpression in
the brain ameliorated neurodegeneration in a Parkin-
son’s disease model [46, 47] and reduced Aβ deposition
and toxicity in an AD mouse model [48]. Despite these
promising data, translating the delivery of PGRN into
the brains of human patients is challenging. Alternatively,
the discovery of small molecules that modulate PGRN
Fig. 3 Trehalose increases PGRN expression via increased transcription.
a GRN mRNA levels were quantified from H4 cells after treatment with 0,
50, or 100 mM trehalose for 18 h (n= 2 independent experiments run in
duplicates). The bars represent the mean ± SEM. **Differs from control,
P< 0.01 using one-way ANOVA followed by Dunnett’s comparison
post-hoc test. b Immunoblot of cell lysates from H4 cells treated
with trehalose (100 mM) plus actinomycin D (1 μM) overnight (16 h)
to block new transcription. Results are representative of two
independent experiments
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Fig. 4 The transcription factor EB (TFEB) does not mediate trehalose-induced upregulation of PGRN. a GRN mRNA levels were quantified from wild-type
HeLa (WT) cells or HeLa cells stably over-expressing TFEB-GFP (TFEB-GFP) (n= 3 independent experiments run in duplicate). b WT or TFEB-GFP HeLa cells
were fractionated into cytoplasmic/membrane and nuclear extracts and immunoblotted for total TFEB and PGRN. GAPDH and H3 were used to verify
fractionation efficiency and were used as loading controls. Asterisk (*) denotes non-specific band in nuclear fraction. c Quantification of PGRN expression in
WT or TFEB-GFP HeLa lysates in b. (n= 3 independent experiments). d TFEB-GFP HeLa cells were treated with trehalose (100 mM) or Torin1 (250 nM) for 0,
2, or 24 h and imaged live with a fluorescent microscope to visualize TFEB-GFP localization. e TFEB-GFP HeLa cells were treated with vehicle,
trehalose (100 mM), or Torin1 (250 nM) for 24 h and then fractionated into cytoplasmic/membrane and nuclear extracts and immunoblotted
for total TFEB and PGRN. Asterisk (*) denotes non-specific band in nuclear fraction. f Quantification of nuclear TFEB (top) and cytoplasmic/
membrane PGRN (bottom) from the immunoblots in e. (n = 3 independent experiments). g Immunoblots from whole-cell lysates of HAP1 WT
and TFEB KO cells showing absence of TFEB expression. h GRN mRNA levels were quantified from HAP1 wild-type (WT) and TFEB knock-out
(TFEB KO) cell lines after treatment with vehicle or trehalose (100 mM) for 18 h (n = 3 independent experiments run in duplicate). i HAP1 WT
and TFEB KO cells were treated with vehicle or trehalose (100 mM) for 24 h and then fractionated into cytoplasmic/membrane and nuclear
extracts. Immunoblots for PGRN (cytoplasmic/membrane) and TFEB (nuclear) are shown. j Quantification of PGRN (top) and TFEB (bottom) from
the immunoblots in i (n= 3 independent experiments). In all graphs, the bars represent the mean ± SEM. For a, c; *differs from WT, P< 0.05, **P< 0.01,
using unpaired two-tailed Student’s t-test. For f, h, j; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 using one-way ANOVA followed by
Tukey’s comparison post-hoc test
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expression would have tremendous therapeutic potential
and also shed light on how PGRN expression is regulated.
Currently, there are only two published reports of small
molecules that increase PGRN. First, alkalizing agents and
inhibitors of the vacuolar ATPase (v-ATPase), such as
chloroquine and bafilomycin A1 respectively, strongly en-
hance intracellular PGRN and secretion through an un-
defined post-transcriptional mechanism [25]. However,
these molecules inhibit the autophagy-lysosome pathway
[49, 50], which may exacerbate the disease process of
FTLD-GRN. Second, select histone deacetylase inhibitors,
in particular SAHA, increase PGRN through increased
transcription [13]. Interestingly, SAHA also induces au-
tophagy, possibly through inhibiting mTOR [51]. How-
ever, the molecular target(s) of SAHA are unclear and
long-term administration may be toxic. Most critically,
neither study evaluated the ability of the drugs to affect
PGRN expression in neuronal or in vivo models of GRN
haploinsufficiency. Because BafA1/chloroquine and SAHA
both modulate the autophagy-lysosome pathway, we rea-
soned that other novel compounds that target this path-
way may be used therapeutically to increase PGRN.
In this study, we generated a human GRN reporter con-
struct to measure changes in PGRN expression in cells after
treatment with a commercially available library of known
autophagy-lysosome pathway modulators. We report that
several novel compounds increased PGRN expression
in various cell types, including several common mTOR
inhibitors (rapamycin, PP242, Torin1) and the mTOR-
independent activator of autophagy, trehalose. Torin1
and trehalose increased human GRN transcription re-
porter activity to levels comparable to SAHA (Fig. 1b). It
should be noted that the reporter screen we employed
only identified compounds that modulate GRN at the
transcriptional level, which we confirmed by including
bafilomycin A1 and chloroquine as negative controls.
Therefore, additional compounds in this library may
modulate PGRN expression via post-transcriptional
mechanisms.
Our findings suggest that PGRN expression is upregu-
lated in response to autophagy-lysosome pathway modu-
lation, but is not dependent on mTOR inhibition, and is
in line with growing evidence that PGRN plays a critical,
yet undefined role in the cellular lysosomal pathway
[10, 17, 18, 29, 52]. While mTOR inhibitors increased
PGRN expression in some cell lines (HEK293T, H4,
HeLa), they failed to raise PGRN in more neuronal cell
types under the same treatment conditions, including
neuroblastoma cells and primary mouse neurons, as well
as human iPSC embryoid bodies. Previously, PGRN has
been linked to modulating mTOR signaling pathways
[29, 53, 54] indicating a possible feedback loop;
Fig. 5 Trehalose rescues PGRN deficiency in patient-derived primary fibroblasts. a Top, Immunoblot of cell lysates from primary human fibroblast
(3 controls; CTL, and 3 progranulin mutation; GRN) cell lines treated with vehicle or trehalose (100 mM) for 24 h. Bottom, Immunoblot of conditioned
serum-free media from primary human fibroblast cell lines treated with vehicle or trehalose (100 mM) for 20 h. b Quantification of intracellular PGRN
from immunoblots in a (top). c Quantification of secreted PGRN from immunoblots in a (bottom). d GRN mRNA levels were quantified from control cell
lines (CTL) or progranulin mutation cell lines treated with vehicle or trehalose (100 mM) for 18 h (each individual line run in duplicate on qPCR). e GRN
primary fibroblasts treated with trehalose (100 mM, 20 h) showed increased cytoplasmic staining of PGRN (red) similar to CTL fibroblasts. Scale bar,
10 μm. Nuclei (circles) and cell bodies are outlined in white. In all graphs, the data are normalized to the lowest CTL value for comparison. For b and c,
bars represent individual densitometric measurements from the immunoblots in a and for d, bars represent the mean ± SEM of two qPCR replicate
values. *Differs from untreated GRN, P < 0.05, **P < 0.01, ***P < 0.001, using unpaired two-tailed Student’s t-test
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however, further work is required to determine exactly
how PGRN and the mTOR signaling pathway may
regulate each other in various cell types. Despite the
therapeutic promise of mTOR inhibitors for the treat-
ment of aging and neurodegeneration, long term
inhibition of mTOR is known to have detrimental side
effects [55, 56]. Therefore, molecules that activate au-
tophagy independent of mTOR inhibition may hold
more therapeutic value for diseases that will require
long-term dosing. Alternatively, trehalose and mTOR
Fig. 6 Trehalose rescues PGRN deficiency in induced pluripotent stem cell (iPSC) embryoid bodies (EBs) and iPSC-derived neurons. a Immunofluorescence
verifies that iPSC colonies generated from control and GRN-mutation patients express the following standard pluripotent stem-cell markers: pluripotent
transcription factors Oct4, Nanog, and Sox2 (green) and surface markers SSEA4, TRA 1–81, and TRA 1–60 (red). b Representative phase images of embryoid
body (EB) formation during differentiation and highly pure iPSC-derived neurons approximately 1-week post plating. c Immunoblot of embryoid body
cell lysates generated from one CTL and one GRN iPSC lines after treatment with vehicle, trehalose (100 mM), or PP242 (1 μM) for 24 h. d Representative
Immunoblot of cell lysates from GRN iPSC-derived neurons treated with trehalose (100 mM) for 24 h. Two independent replicates from the GRN iPSC-
neurons are shown. An untreated control (CTL) patient iPSC-neuron lysate was included to show relative differences in PGRN expression levels.
e Quantification of PGRN expression from vehicle and trehalose treated GRN iPSC-neurons (n = 5 independent experiments for each). In all graphs, the
bars represent the mean ± SEM. ***Differs from control, P < 0.001 using unpaired two-tailed Student’s t-test
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inhibitors may be used synergistically to treat neurode-
generation [20].
We focused on the compound trehalose for further
study because it increased PGRN independent of mTOR
inhibition in all cell lines tested, including patient fibro-
blasts and iPSC-derived neurons. Trehalose is a natural
disaccharide found in bacteria, yeast, insects, fungi, and
plants where it plays a critical role in stress and drought
resistance; but it is not produced in vertebrates (reviewed
in [42]). It is comprised of two α, α-1, 1-glycosidic-linked
D-glucose molecules and is 45 % as sweet as sucrose.
Trehalose is not easily hydrolyzed and does not react
Fig. 7 Oral trehalose administration increases PGRN and LC3-II in Grn+/− mouse brain. a Immunoblot of PGRN and LC3-II from brain lysates of
treated Grn+/− animals. Grn+/+ and Grn−/− brain lysates included as controls for PGRN immunoreactivity. b PGRN was significantly increased in
trehalose treated mice compared to vehicle (*P < 0.05) or sucrose (P = 0.1) treated mice by immunoblot. c Brain PGRN was significantly increased
in trehalose treated mice compared to vehicle (**P < 0.01) or sucrose (**P < 0.01) treated mice by ELISA. d Immunoblot and ELISA PGRN levels
were positively and significantly correlated. e LC3-II was significantly increased in trehalose treated mice compared to vehicle (*P = 0.05) or sucrose
(*P < 0.05) treated mice by immunoblot. f PGRN and LC3-II were positively and significantly correlated across all animals by immunoblot. In b, c, and e,
each measurement per animal is plotted with the mean ± SEM shown for each group. Statistical differences were calculated by one-way
ANOVA followed by Tukey’s comparison post hoc test
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with free amino groups in non-enzymatic glycation re-
actions. It is used in some food products as a stabilizer
and has been designated Generally Regarded as Safe
(GRAS) by the Food and Drug Administration (FDA).
As a neuroprotectant, trehalose increases autophagic
flux in neurons both in vitro [57] and in vivo [58]
through an undefined mechanism and we report here a
similar effect in primary neurons from mouse and
GRN iPSC-derived neurons. Trehalose also reduces ac-
cumulation of commonly misfolded proteins, in vitro
and in vivo, that cause neurodegeneration including
Aβ [48, 59], tau [38, 57, 60, 61], polyglutamine aggre-
gates [39], mutant huntingtin [20, 62, 63], mutant
SOD1 [23, 64], α-synuclein [20, 65–67], prion protein
[68, 69], and TDP-43 [70] via its molecular chaperone
and autophagy-activating properties. It is also worth not-
ing that trehalose clears lipofuscin, a lysosomal storage
material found in FTLD-GRN and AD patients, via activa-
tion of autophagy [71]. Finally, trehalose also acts as an
anti-oxidant and anti-inflammatory molecule in several in
vitro and in vivo models [72–74]. As such, trehalose may
provide therapeutic benefit for the treatment of degenera-
tive diseases via multiple mechanisms. Trehalose is cur-
rently being tested in clinical trials for reversal of arterial
aging (ClinicalTrials.gov Identifier: NCT01575288) and
for treatment of Oculopharyngeal Muscular Dystrophy
(ClinicalTrials.gov Identifier: NCT02015481) and Spi-
nocerebellar Ataxia 3 (ClinicalTrials.gov Identifier:
NCT02147886).
Our results indicate that trehalose increases PGRN
protein levels, at least in part, by increasing GRN tran-
scription, similar to SAHA [13]. However, additional
mechanisms such as enhanced protein stability cannot
be ruled out. It is unknown what transcription factor(s)
may be involved in the trehalose-mediated upregulation
of GRN expression, although we have shown that the
transcription factor EB (TFEB) is not necessary for its ef-
fect. TFEB is strongly regulated by mTOR phosphoryl-
ation, so perhaps it is not surprising that trehalose,
which does not inhibit mTOR, is not a robust activator
of TFEB. Future work will focus on identifying additional
transcription factors activated by trehalose which may
provide further mechanistic insights into GRN transcrip-
tional regulation and additional therapeutic targets.
This is the first report demonstrating the ability of a
small molecule to enhance PGRN expression in patient-
derived GRN deficient neurons, as well as in an in vivo
mouse model of Grn haploinsufficiency. Remarkably, we
saw a significant increase in endogenous PGRN and LC3-II
expression in brain tissue of trehalose treated mice com-
pared to vehicle or sucrose treated mice. The sucrose
treated mice served as an important control as the lack of
effect on PGRN in these mice indicates that disaccharide
hydrolysis into glucose monomers was not responsible for
the increased PGRN expression detected. Due to the
fact that we used young (3 month old) Grn+/− mice
which do not have any known pathological or behavioral
abnormalities [75], we were not able to assess the effects
of trehalose on these parameters. It would be interesting
to test whether trehalose can prevent or reverse neuro-
pathology or behavioral deficits in aged Grn−/− mice in-
dependent of modulating PGRN expression and is a focus
of future studies. Currently, relatively high concentrations
of trehalose are needed to stimulate autophagy in vitro
due to its slow penetrance of cell membranes via fluid-
phase endocytosis [20] and we found that similar trehalose
concentrations were needed to induce PGRN expression.
Similarly, it is unclear if trehalose crosses the blood–
brain-barrier to reach the brain, although it has previously
been reported to do so [39]. Identification or synthesis of
novel trehalose derivatives that have increased metabolic
stability [76], increased cell penetrance [77] or alternative
modes of delivery such as intravenous (IV) infusion may
result in lower doses and enhanced bioactivity needed to
achieve PGRN upregulation and will be explored in future
studies.
Conclusions
In this study, we report the novel finding that trehalose
induces PGRN expression in in vitro and in vivo models
of PGRN deficiency. Trehalose has pleiotropic properties
that make it an attractive neuroprotectant. Moreover,
trehalose is FDA-approved and is currently being tested in
several clinical trials as an autophagy modulator. Based on
our current findings, we conclude that trehalose should be
explored as a first-generation therapeutic treatment for
frontotemporal dementia with GRN mutations as well as
other neurodegenerative diseases such as AD and PD,
where reduced PGRN may be a risk factor.
Additional file
Additional file 1: Table S1. List of top compounds identified from the
autophagy-lysosome library that increase GRN reporter activity. *, S.D. =
standard deviation; **, Z-score = (compound normalized activity – average
normalized activity)/population S.D. Figure S1. Validation of mTOR inhibitors
on PGRN expression in cultured cells. a Dose–response of mTOR inhibitors
in H4 neuroglioma cells. Cells were treated for 24 h and whole cell lysates
were analyzed for PGRN expression as well as autophagy induction
(p62 and LC3-II). P-S6 and P-4EBP1 were used to monitor mTOR inhibition.
Results are representative of two independent experiments. Figure S2.
Trehalose treatment increases autophagic flux without affecting lysosomal
acidification or cell viability. a Immunoblot of cell lysates from H4 cells
showing increased autophagic flux with trehalose treatment. b Quantification
of autophagic flux data in a, (n= 3 independent experiments). **P< 0.01,
***P< 0.001, **** P< 0.0001 using one-way ANOVA followed by Tukey’s
comparison post-hoc test. c LysoTracker red staining of live H4 cells after 24-h
treatment with vehicle (DMSO), bafilomycin A1 (50 nM), or trehalose (50 mM
and 100 mM). Scale bar, 100 μM. Images are representative of two
independent experiments. d Dose- and time-dependent cell viability
after trehalose treatment in H4 cells using trypan-blue exclusion assay, (n = 3
independent experiments measured in duplicate). Statistical differences
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were calculated by one-way ANOVA followed by Dunnet’s comparison post-
hoc test. No significant differences were found for individual treatment
groups compared to untreated control. In all graphs, the bars represent
the mean ± SEM. Figure S3. Trehalose treatment increases PGRN expression
in neuroblastoma cell lines in a dose- and time-dependent manner.
a Immunoblot of cell lysates from human SH-SY5Y neuroblastoma cells
treated with increasing concentrations of trehalose for 24 h. b Immunoblot
of cell lysates from human SH-SY5Y cells treated with 100 mM trehalose for
increasing times. c Imunoblot of cell lysates from murine N2a neuroblastoma
cells treated with increasing concentrations of trehalose for 24 h. d GRN
mRNA levels in SH-SY5Y cells after treatment with 100 mM trehalose for
18 h. **P < 0.01 using unpaired two-tailed Student’s t-test. Results are
representative of two independent experiments. In all graphs, the bars
represent the mean ± SEM. Figure S4. Characterization of iPSC-derived
neurons from primary human fibroblast cultures. a iPSC-derived neurons from
a GRN patient express PGRN (green) in cell bodies (arrow) and processes
(arrowheads) and neuronal specific marker TUJ1 (magenta). Nuclei (blue) are
stained with DAPI. Scale bar, 10 μm. b iPSC-derived neurons from a GRN
patient treated with trehalose (100 mM) for 24 h show intense LC3-labeled
puncta (arrows), indicating autophagosome formation, compared to vehicle
treated GRN neurons. MAP2 (magenta) was used as a neuronal marker. Nuclei
(blue) were labeled with DAPI. Scale bar, 10 μm. Figure S5. Oral trehalose
treatment does not affect total water consumption, weight change, or
plasma PGRN levels in Grn+/− mice. a Average daily water consumption in
milliliters (ml) for mice in each treatment group. ****P < 0.0001. b Body
weight in grams (g) over time for each treatment group. c Quantification of
change in body weight (g) for each treatment group over the duration of
the study. d Plasma PGRN levels as determined by Adipogen ELISA. In all
graphs, the bars represent the mean ± SEM. Statistical differences of trehalose
or sucrose groups relative to vehicle group were calculated by one-way
ANOVA followed by Tukey’s comparison post-hoc test. (DOCX 571 kb)
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